Pulmatrix (NASDAQ:PULM) Earns Hold Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Pulmatrix (NASDAQ:PULM) in a report published on Tuesday. The brokerage issued a hold rating on the biotechnology company’s stock.

Pulmatrix Price Performance

Shares of PULM opened at $6.29 on Tuesday. The company has a 50-day moving average of $2.73 and a two-hundred day moving average of $2.27. The stock has a market cap of $22.97 million, a price-to-earnings ratio of -2.38 and a beta of 0.99. Pulmatrix has a one year low of $1.55 and a one year high of $8.44.

About Pulmatrix

Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.